

# Anaplastic Oligoastrocytoma - Pipeline Review, H1 2020

<https://marketpublishers.com/r/A9EEEEAE800BEN.html>

Date: May 2020

Pages: 83

Price: US\$ 2,000.00 (Single User License)

ID: A9EEEEAE800BEN

## Abstracts

Anaplastic Oligoastrocytoma - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anaplastic Oligoastrocytoma – Pipeline Review, H1 2020, provides an overview of the Anaplastic Oligoastrocytoma (Oncology) pipeline landscape.

Anaplastic oligoastrocytoma is a brain tumor that forms when two types of cells in the brain, called oligodendrocytes and astrocytes, rapidly increase in number to form a mass. These brain cells are known as glial cells, which normally protect and support nerve cells in the brain. Symptoms include seizures, headaches, and personality changes. Other symptoms vary by location and size of the tumor. Treatment includes chemotherapy and surgery.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anaplastic Oligoastrocytoma – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Anaplastic Oligoastrocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anaplastic Oligoastrocytoma (Oncology) pipeline guide also reviews of key players

involved in therapeutic development for Anaplastic Oligoastrocytoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I and IND/CTA Filed stages are 3, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Anaplastic Oligoastrocytoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Anaplastic Oligoastrocytoma (Oncology).

The pipeline guide reviews pipeline therapeutics for Anaplastic Oligoastrocytoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Anaplastic Oligoastrocytoma (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Anaplastic Oligoastrocytoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Anaplastic Oligoastrocytoma (Oncology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Anaplastic Oligoastrocytoma (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Anaplastic Oligoastrocytoma (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Global Markets Direct Report Coverage

Anaplastic Oligoastrocytoma - Overview

Anaplastic Oligoastrocytoma - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Anaplastic Oligoastrocytoma - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Anaplastic Oligoastrocytoma - Companies Involved in Therapeutics Development

Astellas Pharma Inc

Bayer AG

Boehringer Ingelheim International GmbH

Nascent Biotech Inc

Pfizer Inc

TheraBiologics Inc

Anaplastic Oligoastrocytoma - Drug Profiles

afatinib dimaleate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bendamustine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

palbociclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pratumumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sorafenib tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TBX.CD + 5-FC - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TBX.CE + irinotecan hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Anaplastic Oligoastrocytoma - Dormant Projects

Anaplastic Oligoastrocytoma - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Anaplastic Oligoastrocytoma, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Anaplastic Oligoastrocytoma - Pipeline by Astellas Pharma Inc, H1 2020

Anaplastic Oligoastrocytoma - Pipeline by Bayer AG, H1 2020

Anaplastic Oligoastrocytoma - Pipeline by Boehringer Ingelheim International GmbH, H1 2020

Anaplastic Oligoastrocytoma - Pipeline by Nascent Biotech Inc, H1 2020

Anaplastic Oligoastrocytoma - Pipeline by Pfizer Inc, H1 2020

Anaplastic Oligoastrocytoma - Pipeline by TheraBiologics Inc, H1 2020

Anaplastic Oligoastrocytoma - Dormant Projects, H1 2020

Anaplastic Oligoastrocytoma - Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Anaplastic Oligoastrocytoma, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

### COMPANIES MENTIONED

Astellas Pharma Inc

Bayer AG

Boehringer Ingelheim International GmbH

Nascent Biotech Inc

Pfizer Inc

TheraBiologics Inc



## I would like to order

Product name: Anaplastic Oligoastrocytoma - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/A9EEEEAE800BEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A9EEEEAE800BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970